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Abstract
Cullin-RING ubiquitin ligase (CRL), with its founding member of SKP1-Cullins-F-box proteins (SCF) E3 ubiquitin ligase,
is the largest family of E3 ligases, which requires cullin neddylation for its activation. Recently, an inhibitor of NEDD8
activating enzyme (NAE), MLN4924, was reported to block cullin neddylation and inactivate CRL/SCF E3, resulting in
apoptosis induction and tumor suppression both in vitro and in vivo. We report here that apoptosis is not the sole
mechanism by which MLN4924 suppresses tumor cell growth because apoptosis is moderately induced by the drug
in some cancer cell lines and drug-induced growth suppression is only partially blocked by a pan-caspase inhibitor,
z-VAD. MLN4924 treatment induces the characteristics of senescence phenotypes as evidenced by enlarged and
flattened cellular morphology and positive staining of senescence-associated β-Gal. MLN4924-induced senescence
is associated with cellular response to DNA damage, triggered by accumulation of DNA-licensing proteins CDT1 and
ORC1, as a result of inactivation of CRL/SCF E3s. The senescence occurs in the manner independent of pRB/p16 and
p53, but dependent on p21, a known substrate of CRL/SCF E3s and a mediator of senescence, which accumulates
on CRL/SCF inactivation by MLN4924. Furthermore, MLN4924-induced senescence is irreversible and coupled with
persistent accumulation of p21 and sustained activation of DNA damage response. Our study reveals a novel mecha-
nism of MLN4924 action and showed that MLN4924 could be further developed as an effective anticancer agent by
inducing apoptosis and irreversible senescence.
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Introduction
The CRL (Cullin-RING ligases), with its founding member of SKP1-
Cullin-F-box proteins (SCF) E3 ubiquitin ligases, is the largest cellular
multiunit ubiquitin ligase [1,2] that promotes the degradation of up to
20% of ubiquitinated cellular proteins [3], thus regulating numerous
biologic processes [4]. Intensive studies demonstrate that CRL/SCF
ubiquitin ligases serve as promising anticancer targets [5,6] owing to
the following characteristics: (a) CRL/SCF E3 ubiquitin ligase is ab-
normally activated in many human cancers, which contributes to un-
controlled proliferation and genomic instability [2]; (b) several subunits
of CRL/SCF E3 ubiquitin ligases, such as SKP2, β-TRCP, CUL4A,
and RING-finger protein ROC1 or ROC2, function as oncoproteins
and are specifically overexpressed in human cancers [7–10]; (c) in-
hibition of CRL/SCF activity or down-regulation of these oncogenic
CRL/SCF components suppresses the growth of cancer cells in vitro
and in vivo [7–9]; and (d) it is a “druggable” enzyme. However, owing
to its multiunit composition, it is technically challenging to set up a
high-throughput screening for small-molecule inhibitors of CRL/SCF
E3 ligases [11].
The core of CRL/SCF ubiquitin ligases is a cullin-RING finger
protein complex [12]. In human and mouse, there are seven cullin
(CUL 1-3, 4A, 4B, 5, and 7) and two RING (RBX1/RBX2) family
members [1,2,6]. Activation of CRL/SCF requires cullin neddylation
[13–17], a modification by adding ubiquitin-like protein NEDD8 to
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cullins, catalyzed by NEDD8-activating enzyme E1 (NAE), NEDD8-
conjugating enzyme E2 (Ubc12), and NEDD8-E3 ligase [18]. Most
recently, an NAE inhibitor, MLN4924, was identified through a high-
throughput screening [3]. MLN4924 binds to NAE to create a covalent
NEDD8-MLN4924 adduct that blocks NAE enzymatic activity [19].
By doing so, MLN4924 efficiently inhibits cullin neddylation, thus
inactivating CRL/SCF E3 ligase to cause substrate accumulation. As
a result, DNA damage response was triggered and apoptosis was
induced, leading to a remarkable anticancer effect both in vitro and
in vivo [3,20,21]. The findings further validate CRL/SCF E3 as a prom-
ising cancer targets [5,6] and demonstrate MLN4924 as a novel class of
anticancer agent. Indeed, MLN4924 has advanced to several phase 1
clinical trials for solid tumors and hematological malignancies [22].
Although the biochemical mechanisms of MLN4924 action are well
defined [19], induction of apoptosis is the only known biologic mecha-
nism by which MLN4924 suppresses cancer cell growth [3,20,21]. In
the present study, we report that MLN4924-mediated apoptosis in-
duction only partially contributes to the growth suppression and that
the other death mechanism involves MLN4924-triggered senescence,
which is an irreversible and p21-dependent process, likely as a con-
sequence of prolonged DNA damage response. Our study demonstrates
that by inducing both apoptosis and senescence through inactivation of
CRL/SCF E3 ligases, MLN4924 acts as an effective anticancer agent
for targeted cancer therapy.
Materials and Methods
Cell Culture and Drug Treatment
Human cancer lines, HCT116 colon (p53-wt), H1299 lung (p53-
null), and U87 glioblastoma (inactive wt p53) were purchased from
ATCC (Manassas, VA). HCT116-p21+/+ versus HCT116-p21−/−
and MEF-p21+/+ versus MEF-p21−/− cells were kindly provided by
Drs Vogelstein and Roberts, respectively, and were authenticated by im-
munoblot analysis with demonstration of expected expression of p21 in
p21+/+ cells but not in p21−/− cells. Other lines were authenticated by
expected p53 expression using immunoblot analysis. Cells were grown
at 37°C in 5% CO2 in McCoy’s medium (HCT116 cells) or Dulbecco
modified Eagle medium (H1299, U87, and MEF cells) supplemented
with 10% fetal bovine serum. Cells were treated with MLN4924 (a gift
from Millennium Pharmaceutical, Inc, Cambridge, MA), followed by
various growth assays and immunoblot analysis.
ATPlite Cell Proliferation Assay
Cells were seeded in 96-well plate and treated with MLN4924 for
72 to 96 hours, followed by ATPlite assay [8,9,23].
Clonogenic Survival Assay
Single-cell suspension was seeded in 60-mm dishes and treated with
MLN4924 for 9 days. Colonies were stained and counted [8,9].
SA-β-Galactosidase Staining
The expression of senescence-associated β-galactosidase was deter-
mined by SA-β-Galactosidase (SA-β-Gal) staining [8,9,24] after expos-
ing cells to MLN4924 at 0.1 μM for 72 to 80 hours.
Immunoblot Analysis
Cell lysates were prepared for immunoblot analysis using antibodies
against p16, total and pRB, WEE-1, and caspase-3 (Santa Cruz Bio-
technology, Santa Cruz, CA); p53 (Calbiochem, Gibbstown, NJ);
ORC-1, CDT1, and p21 (BD Biosciences, San Diego, CA); β-actin
(Sigma, St Louis, MO); phospho-gamma H2A (Ser 139; Millipore,
Billerica, MA); and poly (ADP-ribose) polymerase and phospho-CHK1
(Cell Signaling, Danvers, MA).
FACS Analysis and DNA Fragmentation Assay
Cells were treated with various doses of MLN4924 for various periods,
followed by FACS analysis and DNA fragmentation assay [8,9,23].
Microscopy
Cellular morphology and SA-β-Gal staining were captured by
Olympus 1X71 using Olympus LCP LAN F1 lens and Olympus
DP70 cameras (Olympus Optical Co. Ltd, Center Valley, PA). The
acquisition software used is the Olympus DP Controller 2002
(Olympus Optical Co, Ltd).
Results
Apoptosis Is Not the Only Mechanism by Which MLN4924
Induced Growth Suppression
MLN4924, a potent NAE inhibitor, was recently reported to block
cullin neddylation, thus inactivating CRL/SCF E3 ligase to cause
accumulation of a number of its substrates, leading to suppression of
tumor cell growth both in vitro and in vivo by inducing abnormal cell
cycle progression and apoptosis [3,20,21]. We determined the efficacy
of MLN4924 against the growth of several human cancer cell lines,
including HCT116, H1299, and U87 cells. MLN4924 effectively in-
hibited cancer cell proliferation with the half-maximal inhibitory concen-
tration (IC50) value ranging from 22 to 87 nM (Figure 1A). MLN4924
was also a potential inhibitor of cancer cell clonogenic survival with an
IC50 less than 50 nM (Figure 1B). To explore the apoptosis mecha-
nism of MLN4924 action, we measured formation of cleaved PARP
and caspase-3, two hallmarks of apoptosis. As shown in Figure 1C ,
MLN4924 caused a limited cleavage of PARP and caspase-3, particu-
larly at a low drug concentration in HCT116 cells, but not in H1299
cells even at high drug concentrations. A minor cleavage of PARP, but
not of caspase-3, was observed in U87 cells. We further determined the
involvement of apoptosis in MLN4924-induced growth suppression
by a rescuing experiment using z-VAD, a pan-caspase inhibitor and ex-
pected a full rescue if apoptosis is the sole mechanism. Consistent with
our PARP and caspase-3 cleavage results, z-VAD only partially rescued
MLN4924-induced growth suppression in HCT116 cells, but not in
U87 and H1299 cells (Figure 1D). Taken together, the findings indi-
cated that MLN4924-induced apoptosis only partially contributes to
observed growth suppression and suggested the involvement of other cell
killing mechanism.
Senescence Is Induced by Low Dose of MLN4924
We recently showed that small interfering RNA silencing of ROC1/
RBX1, a RING component of CRL/SCF E3 ligase required for its
activity, induced, in addition to apoptosis, senescence, which was associ-
ated with DNA damage response [8]. We therefore determined whether
pharmacological inactivation of CRL/SCF E3 ligase by MLN4924
would also induce senescence. Indeed, all three lines of cancer cells after
MLN4924 treatment at 0.1 μM concentration demonstrated an en-
larged and flattened shape, a reminiscence of senescence phenotype
(Figure 2A, top three panels). SA-β-Gal staining showed that ∼50%
of HCT116 cells were stained positively compared with only ∼1%
cells with positive staining in the DMSO control group (Figure 2A,
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Figure 1. Effect of MLN4924 on cell growth and apoptosis. (A) Sensitivity of cancer cells to MLN4924: Cells were seeded in 96-well plates
in triplicate and treated with various MLN4924 doses for 72 hours, followed by ATPlite assay. Shown is mean ± SEM (n = 2). (B) Effect
of MLN4924 on clonal survival of human cancer cells: Cells were seeded in 60-mm dishes in duplicate and treated with MLN4924 at indi-
cated concentration (μM) for 9 days, followed by colony staining and counting. A representative experiment is shown (n=3). (C) Induction of
cleavage of PARP and caspase-3: Cells were treatedwithMLN4924 for 24 hours, followed by immunoblot analysis. cPARP indicates cleaved
PARP; cCasp3, cleaved caspase-3. *Nonspecific band. (D) Partial rescue of MLN4924-induced growth suppression by z-VAD: Cells were
seeded in 96-well plates in triplicate and treated with 40 μMof z-VAD for 4 hours before MLN4924 (μM) treatment for 96 hours, followed by
ATPlite assay with light units reflecting cell growth. Shown is a representative experiment (n = 3). Paired Student’s t test was performed.
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bottom panel ). MLN4924-induced SA-β-Gal staining was also seen in
H1299 and U87 cells after prolonged staining (data not shown). Thus,
MLN4924 could also induce senescence in addition to apoptosis.
It has been recently shown that DNA rereplication triggers a DNA
damage response to mediate oncogene-induced senescence [25,26].
Because both CDT1 and ORC1 are critically involved in DNA rep-
lication [27–29] and are substrates of CRL/SCF E3 ligases [30–33],
we determined whether CDT1 and ORC1 were accumulated on
MLN4924 treatment. We first confirmed that MLN4924 indeed in-
hibited cullin-1 neddylation even at 0.1 μM (Figure 2B, top). We then
found that MLN4924 induced a dose- (Figure 2B, panels 2 and 3) and
time-dependent (Figure 2C ) accumulation of CDT1 and ORC1 in
all three lines. Consistent with a recent report showing that CDT1
overexpression caused double-strand breaks and triggered a DNA
damage response, followed by senescence induction [34], we found
that MLN4924 treatment also triggered DNA damage response in
all three cancer lines, as evidenced by induction of phospho-CHK1
and phospho-H2AX, which was again in a dose-dependent manner
(Figure 2, B, panels 4 and 5, and D). These results suggest that senes-
cence induction is a universal response of cancer cells to MLN4924,
which is consistent with the notion that, by inhibiting cullin neddyla-
tion, MLN4924 inactivates CRL/SCF E3 ligases and causes accumu-
lations of DNA-licensing proteins, CDT1 and ORC1, to trigger DNA
damage response, leading to senescence.
MLN4924-Induced Senescence Is Independent of p16/pRB/
p53, But Dependent on p21, a Substrate of CRL/SCF E3
Ubiquitin Ligases
The p16/pRB and p53/p21 axes are two major senescence-triggering
pathways in response to stresses [35]. To elucidate the mediators of
MLN4924-induced senescence, we determined the activation status of
these pathways in MLN4924-treated cells. Although p16 is undetect-
able, consistent with the fact that these cell lines are p16-null [36,37],
both total and phosphorylated levels of RB, a reported SCF substrate
only when E7 oncoprotein or EB virus laten antigen 3C was present
[38,39], did not change on MLN4924 treatment (Figure 3A), exclud-
ing the involvement of the p16/pRB axis. We then investigated the role
of the p53/p21 axis in MLN4924-mediated senescence. As shown in
Figure 2. Induction of senescence (A) and CRL/SCF E3 substrates and DNA damage response (B–D). Cells were treated with MLN4924
at 0.1 μM for 80 hours, followed by morphological observation (A, top three panels) and SA-β-Gal staining (A, bottom). Photographs were
taken using Olympus DP70 camera (×400) with size bar shown. Cells were treated with MLN4924 for 24 hours at various concentrations
(B, D) or for indicated time periods at 0.1 μM (C), followed by immunoblot analysis.
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Figure 3 (A and B), p53 was accumulated in HCT116 cells after drug
treatment in dose- and time-dependent manners. However, p53, expressed
at a high basal level, was not further induced on drug treatment in U87
cells harboring a nonfunctional wild-type p53 [8,40]. As expected, no p53
was detectable in p53-null H1299 cells [41]. The fact that senescence
induction in all three cancer lines, regardless of their p53 status, suggests
that MLN4924-induced senescence may not require a functional p53.
In contrast, p21, a known substrate of CRL/SCF [2,42–44] and an
effective senescence mediator [35,45], was accumulated in a dose- and
time-dependent manner in all three lines of cancer cells treated with
MLN4924 (Figure 3, A and B), suggesting that p21 may play an es-
sential role in MLN4924-induced senescence. To test this hypothesis,
we used two pairs of cell lines: HCT116-p21+/+ versusHCT116-p21−/−
and mouse embryonic fibroblasts (MEFs) with p21+/+ versus p21−/−
background. As shown in Figure 4A, MLN4924 treatment induced
senescence in 50% of HCT116-p21+/+ cells, but only 13% of HCT-
116-p21−/− cells, demonstrating that p21 confers an approximate four-
fold increase in sensitivity. Likewise, p21+/+ MEFs were approximately
five-fold more sensitive than p21−/− MEFs to MLN4924-induced se-
nescence with 15% versus 2.7% of population undergoing senescence,
respectively (Figure 4B). Thus, MLN4924-induced senescence seems
to be largely p21-dependent.
p21-Mediated Senescence Contributes to MLN4924-Induced
Growth Suppression
To determine whether senescence induction directly contributes to
MLN4924-mediated growth suppression, we compared the drug sen-
sitivity of paired HCT116 cells with or without p21 and found that
HCT116-p21+/+ cells were ∼2.5-fold more sensitive to MLN4924
than HCT116-p21−/− cells with an IC50 value of 47 versus 118 nM
(Figure 4C ). Similarly, p21+/+ MEF cells were approximately four-fold
more sensitive to the drug than p21−/− MEF cells with an IC50 value of
0.9 versus 4.0 μM (Figure 4D). Detection of basal and induced levels
of p21 was shown in p21+/+ but not in p21−/− cells (Figure 4, C and
D). Taken together, p21-mediated senescence directly contributed
to MLN4924-induced growth suppression. However, the fact that
MLN4924 still caused growth suppression of p21−/− cells suggests
that induction of senescence is not the only mechanism by which
MLN4924 suppresses cell growth.
p21 Is a Survival Factor That Protects HCT116 Cells from
Apoptosis Induced by MLN4924
We next determined relative contribution of MLN4924-induced
apoptosis to growth suppression in paired HCT116 cells with or with-
out p21 expression. It has been well established that p21 plays a sur-
vival role in preventing p53-dependent apoptosis on DNA damage,
particularly in HCT116 cells [46]. We, therefore, hypothesized that
in contrast to MLN4924-induced senescence, HCT116-p21−/− cells
would be more sensitive than p21+/+ cells to MLN4924-induced apop-
tosis. Indeed, using two independent measures of apoptosis, namely,
FACS analysis for sub-G1 apoptotic population (Figure 5A) and DNA
fragmentation (Figure 5B), we found that MLN4924 induced dose-
and time-dependent apoptosis in both lines, with HCT116-p21−/−
cells being about two-fold more sensitive than p21+/+ cells. Thus, p21
also plays a survival role against apoptosis induced by MLN4924, an
enzyme inhibitor that does not directly cause DNA damage. Given
the fact that HCT116-p21+/+ cells were more sensitive to senescence
but more resistant to apoptosis with an overall higher sensitivity to
Figure 3. MLN4924 induces p21. Cells were treated with MLN4924 for 24 hours at various concentrations (A) or with 0.1 μM of
MLN4924 for various time points (B), followed by immunoblot analysis with indicated antibodies.
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drug-induced growth suppression (2.5-fold lower IC50 than that in
HCT116-p21−/− cells), we concluded that senescence contributes more
than apoptosis to MLN4924-induced growth suppression.
MLN4924-Induced Senescence Is Irreversible, Which Is
Associated with Prolonged p21 Accumulation and DNA
Damage Response
Having established that senescence induction is a critical anti-
cancer mechanism by MLN4924, we next determined whether
MLN4924-induced senescence is reversible. Cells were treated with
MLN4924 at 0.1 μM for 72 hours to induce senescence-like mor-
phologic changes, followed by either drug removal and cell culture
in drug-free medium for additional 72 hours or continued incubation
in drug-containing medium for an additional 72 hours. As shown in
Figure 6A for both HCT116 and H1299 cells as well as U87 cells (data
not shown), the senescence-like morphologic changes were similar be-
tween two groups of cells regardless of MLN4924 removal, suggesting
that removal of MLN4924 failed to revert the senescence phenotype.
The clonogenic survival assay also showed that MLN4924-induced
suppression of clonal survival was not reversible either after the removal
of the drug (Figure 6B, and data not shown for U87 cells). Thus,
MLN4924-induced senescence is irreversible.
To address the molecular basis for the irreversibility of MLN4924-
induced senescence, we determined the dynastic changes of a subset
Figure 4. MLN4924-induced senescence is p21 dependent. Cells were treated with MLN4924 at 0.1 μM (HCT116; A) or 1.0 μM (MEFs;
B) for 80 hours, followed by SA-β-Gal staining. The percentage of cell population undergoing senescence were quantified by counting
blue cells out of total cells in four to five independent areas. Shown is percent β-Gal–positive cells averaged from two independent
experiments. Photographs were taken using Olympus DP70 camera (×200) with size bar shown. P < 0.01 by Student’s t test between
paired p21+/+ and p21−/− cells in both HCT116 and MEFs on MLN4924 treatment. Paired HCT116 cells (p21+/+ vs p21−/−) (C) or MEF
cells (p21+/+ vs p21−/−) (D) were treated with MLN4924 at 0.1 or 1.0 μM for 80 hours, respectively, followed by immunoblot analysis
(top), or with MLN4924 at various concentrations for 72 hours, followed by ATPlite assay. Shown is mean ± SEM from two independent
experiments (bottom).
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of the CRL/SCF substrates (WEE1, ORC1, and p21) and of DNA
damage response proteins (pCHK1 and pH2AX) at 72 hours after
MLN4924 treatment and thereafter at the various time points after
the drug removal. As shown in Figure 6C , the CRL/SCF substrates
WEE1 [47] and ORC1 [31] were expectedly accumulated at 72 hours
after MLN4924 treatment and subsequently decreased on drug re-
moval, suggesting that drug removal resulted in reactivation of CRL/
SCF E3 ubiquitin ligase. Interestingly, p21, on accumulation by
MLN4924, remained elevated in HCT116 cells or even continued
to accumulate in H1299 cells (Figure 6C) after drug removal. More-
over, two phosphorylated proteins, pCHK1 and pH2AX, reflecting
the cellular DNA damage response, which is a potential trigger of cell
senescence [25,26], also remained at the elevated levels on drug removal
(Figure 6C). The results suggest that persistent p21 accumulation and
sustained activation of DNA damage response after drug removal
contributed to the irreversibility of MLN4924-induced senescence.
Discussion
Induction of apoptosis was previously defined as the mechanism of
MLN4924 action for growth suppression of solid and hematopoietic
tumor cells [3,20,21]. While this article was at the late stage of prepa-
ration, Lin et al. [48] reported that MLN4924 could also induce senes-
cence in PC3 prostate cancer cells with both p53-null and PTEN-null
background. Here we showed in three cancer lines that, in addition to
apoptosis induction, MLN4924 also induces cellular senescence after a
prolonged treatment at low drug concentrations, which contributes to
growth suppression. Our mechanistic study revealed that MLN4924-
induced senescence is associated with DNA damage response, likely
triggered by DNA rereplication due to accumulation of DNA-licensing
proteins (e.g., CDT1 and ORC1), resulting from inactivation of CRL/
SCF E3 ligases. Furthermore, the senescence occurs in a manner indepen-
dent of p16/pRB/p53, but dependent of p21, and is irreversible. Irrevers-
ibility of MLN4924-induced senescence is associated with sustained
elevation of p21 and prolonged activation of DNA damage response.
While this article was under the review, Lin et al. [49] reported
similar findings that MLN4924 triggered checkpoint activation and
induced apoptosis and senescence, with main focus in HCT116 cells.
Comparison of our study with the study by Lin et al. revealed several
similarities and discrepancies. The similarities include the following:
1) MLN4924 triggers DNA damage response by inducing CDT1 ac-
cumulation, 2) MLN4924 induces both apoptosis and senescence,
and 3) senescence is p21 dependent and irreversible. The discrepancies
from our study include the following: 1) senescence is p53 dependent
as well, although to a lesser extent; and 2) p53/p21-null cells were
more sensitive to the drug [49]. These discrepancies can be partly ex-
plained by the fact that our senescence study was conducted under
low drug concentration (0.1 μM) with prolonged period of exposure
(72-80 hours) versus their high drug concentration (1 μM) with short
exposure (8 hours) [49]. In addition, based on their study mainly con-
ducted in a single HCT116 line, Lin et al. [49] concluded that apopto-
sis, not senescence, might be more important for the antiproliferative
effect of MLN4924. Although our study was not geared to determine
which mechanism is the major contributor to MLN4924-induced
growth suppression rather than focus on senescence as a novel mecha-
nism, we did observe that 1) apoptosis contributed less than senes-
cence to MLN4924-induced growth suppression in HCT116 cells
(Figures 4 and 5) and 2) apoptosis contributed little, if any, to drug-
induced growth suppression inH1299 and U87 cells (Figure 1). Never-
theless, a drug concentration–dependent switch between apoptosis and
senescence in HCT116 cells with or without p53 or p21 was previously
reported after treatment with anticancer drug camptothecin [50]. Taken
together, it seems that MLN4924 induces both apoptosis and senes-
cence, and the contribution of eachmechanism to its growth suppression
activity would likely be dependent on cellular context, drug concentra-
tions used, and duration of drug treatment.
Figure 5. p21-null HCT116 cells are more sensitive to apoptosis induced by MLN4924. (A) Paired HCT116 cells were treated with various
doses of MLN4924 for 24 hours, followed by FACS analysis for sub-G1 apoptotic population. Shown is mean ± SEM from two independent
experiments. *P < 0.05 by Student’s t test. (B) Paired HCT116 cells were treated with various doses of MLN4924 for 24 or 48 hours,
respectively, followed by DNA fragmentation assay, run in 1.8% agarose gel. Lanes 1 and 6, DMSO controls; lanes 2/3 and 7/8, 0.3 μM
for 24/48 hours; lanes 4/5 and 9/10, 1.0 μM for 24/48 hours, respectively. M indicates molecular marker.
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In summary, our study elucidated a new mechanism of MLN4924
action by inducing senescence to suppress cancer cell growth. In addi-
tion, it provides three useful aspects with regards to future development
of MLN4924 as a novel class of anticancer agent [22]. First, MLN4924
induces senescence largely independent of p53. Virtually all human
cancers regardless of p53 status can be treated by the drug. Second,
MLN4924 induces senescence irreversibly at low drug concentrations,
which makes it possible to use low doses of the drug to achieve a greater
therapeutic index, given the fact that normal fibroblasts are much more
resistant to the drug. Third, prolonged p21 accumulation and DNA
damage response could serve as useful biomarkers for target modulation
by MLN4924.
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